Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF

Primary Myelofibrosis (MF) Clinical Trial

Official title: A Multi-national Open-label Phase II Study of the JAK Inhibitor INC424 in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis

Status Completed

Clinical Trial Summary

The objective of this study was to determine the efficacy of INC424 as assessed by reduction in spleen volume in patients with primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF. The safety and tolerability of INC424 and the effects of INC424 on patient reported outcomes and the duration of response as assessed by reduction in spleen volume was also assessed.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Polycythemia
• Polycythemia Vera
• Post-Essential Thrombocythemia (ET) MF
• Post-Polycythemia Vera (PV) MF
• Primary Myelofibrosis
• Primary Myelofibrosis (MF)
• Thrombocythemia, Essential
• Thrombocytosis

• NCT number: NCT01392443
• Study type: Interventional
• Source: Novartis
• Status: Completed
• Phase: Phase 2
• Start date: October 14, 2010
• Completion date: October 31, 2017